PMID- 29273130
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20190111
IS  - 1534-4436 (Electronic)
IS  - 1081-1206 (Linking)
VI  - 120
IP  - 1
DP  - 2018 Jan
TI  - Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis.
PG  - 53-58
LID - S1081-1206(17)31171-7 [pii]
LID - 10.1016/j.anai.2017.10.009 [doi]
AB  - BACKGROUND: Local allergic rhinitis (LAR) is a relatively new disease. OBJECTIVE: 
      To ascertain the effects of allergen-specific immunotherapy in LAR. METHODS: A 
      randomized, double-blind, placebo-controlled trial of birch subcutaneous allergen 
      immunotherapy (AIT) for LAR was performed in 28 patients. The therapy was 
      performed for 24 months in 15 patients with AIT and 13 patients given placebo. 
      The primary end point was decrease in symptom medication score (SMS). In 
      addition, we monitored serum-specific immunoglobulin E (IgE), serum-specific 
      immunoglobulin G4, nasal-specific IgE to Bet v 1, and safety and quality-of-life 
      parameters. RESULTS: After 24 months of treatment, there was a significant 
      decrease in the median area under the curve for SMS of the active group vs the 
      placebo group: 2.14 (range, 1.22-4.51) vs 6.21 (range, 5.12-7.89), at the P < .05 
      level. During AIT, the active group showed a significant decrease in SMS of up to 
      65% vs baseline. A significant increase in immunoglobulin G4 and decrease in 
      nasal-specific IgE were observed in the active group during AIT compared with the 
      placebo group. AIT was well-tolerated and without systemic reactions. CONCLUSION: 
      This study demonstrates that AIT for birch pollen in patients with LAR was 
      clinically effective and exhibited good tolerance. TRIAL REGISTRATION: 
      ClinicalTrials.gov Identifier: NCT03157505.
CI  - Copyright (c) 2017 American College of Allergy, Asthma & Immunology. Published by 
      Elsevier Inc. All rights reserved.
FAU - Bozek, Andrzej
AU  - Bozek A
AD  - Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, 
      Medical University of Silesia, Katowice, Poland. Electronic address: 
      andrzejbozek@o2.pl.
FAU - Kolodziejczyk, Krzysztof
AU  - Kolodziejczyk K
AD  - Allergy Outpatient Clinic, Katowice, Poland.
FAU - Jarzab, Jerzy
AU  - Jarzab J
AD  - Clinical Department of Internal Disease, Dermatology and Allergology in Zabrze, 
      Medical University of Silesia, Katowice, Poland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03157505
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Ann Allergy Asthma Immunol
JT  - Annals of allergy, asthma & immunology : official publication of the American 
      College of Allergy, Asthma, & Immunology
JID - 9503580
RN  - 0 (Antigens, Plant)
RN  - 0 (Immunoglobulin G)
RN  - 126161-14-6 (Bet v 1 allergen, Betula)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, Plant/immunology/*therapeutic use
MH  - Betula/immunology
MH  - Desensitization, Immunologic/*methods
MH  - Female
MH  - Humans
MH  - Immune Tolerance
MH  - Immunoglobulin E/blood
MH  - Immunoglobulin G/blood
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Pollen/immunology
MH  - Quality of Life
MH  - Rhinitis, Allergic/*immunology
MH  - Young Adult
EDAT- 2017/12/24 06:00
MHDA- 2019/01/12 06:00
CRDT- 2017/12/24 06:00
PHST- 2017/09/12 00:00 [received]
PHST- 2017/09/29 00:00 [revised]
PHST- 2017/10/04 00:00 [accepted]
PHST- 2017/12/24 06:00 [entrez]
PHST- 2017/12/24 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
AID - S1081-1206(17)31171-7 [pii]
AID - 10.1016/j.anai.2017.10.009 [doi]
PST - ppublish
SO  - Ann Allergy Asthma Immunol. 2018 Jan;120(1):53-58. doi: 
      10.1016/j.anai.2017.10.009.